[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362857-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362857-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recent-advances-in-nanocarrier-based-drug-delivery-systems-for-lung-cancer","Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer","","Lung cancer remains the leading cause of cancer-related death worldwide, and conventional care such as surgery, radiotherapy, and chemotherapy is constrained by limited tumor selectivity, low bioavailability, and systemic toxicity. Nanocarriers are colloidal platforms with tunable size, high surface area, and stimuli-responsiveness, enabling nanocarrier-based drug delivery systems (NDDSs) for targeted delivery, controlled release, and theranostics. This review evaluates advantages, limitations, and clinical translation across organic, inorganic, and hybrid nanodelivery classes, and outlines future directions including deep-lung inhalation optimization, multi-target biomimetic carriers, improved theranostic platforms, and computational acceleration for design.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recent-advances-in-nanocarrier-based-drug-delivery-systems-for-lung-cancer/362857/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recent-advances-in-nanocarrier-based-drug-delivery-systems-for-lung-cancer/362857.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are conventional lung cancer treatments limited?","Question",{"text":63,"@type":64},"Conventional approaches like surgery, radiotherapy, and chemotherapy can suffer from poor tumor selectivity, low bioavailability, and severe systemic toxicity, which reduces treatment efficacy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What makes nanocarrier-based drug delivery systems promising for lung cancer?",{"text":68,"@type":64},"Nanocarriers provide tunable size, high specific surface area, and stimuli-responsive behavior, supporting targeted delivery, controlled drug release, and theranostic capabilities.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the review categorize nanodelivery systems for lung cancer?",{"text":72,"@type":64},"The review discusses three major classes: organic, inorganic, and inorganic–organic hybrid nanodelivery systems, highlighting their distinct properties and roles in therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362857,1790195001,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nRecent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer  \nZhengjun Li 1 , *, Chang Liu 1 , *, Zexi Di2 , *, Guofeng Zhang 1 , Sibo You 1 , Siwei Chao 3 , Yi Ren 1  \n1Department of Thoracic Surgery, Shenyang Chest Hospital, Shenyang, 110044, People’s Republic of China; 2Central Hospital Affiliated to Shenyang Medical College, Shenyang Medical College, Shenyang, 110024, People’s Republic of China; 3Shenyang Medical College, Shenyang, 110034, People’s Republic of China  \n*These authors contributed equally to this work Correspondence: Yi Ren, Email [renyisyxk@126.com](renyisyxk@126.com)  \n\n| Abstract: Lung cancer (LC) remains the leading cause of cancer-related deaths globally. Conventional therapeutic strategies, including surgery, radiotherapy, and chemotherapy, are often hampered by limitations such as poor tumor selectivity, low bioavailability, and severe systemic toxicity, which compromise treatment efficacy. Nanocarriers are colloidal formulations characterized by abundant porosity and unique physicochemical properties, such as tunable size, high specific surface area, and stimuli-responsiveness. Nanocarrier-based drug delivery systems (NDDSs) have emerged as a promising solution to enable targeted delivery, controlled drug release, and theranostics. This review discusses the advantages, limitations, and clinical translation of three major classes of nanodelivery systems for LC therapy: organic, inorganic, and inorganic–organic hybrid nanosystems. Organic systems are characterized by high biocompatibility and versatile drugloading capacity, whereas inorganic counterparts provide distinctive optical or magnetic functionalities that enable imaging and synergistic therapy. Hybrid designs integrate both material classes to improve stability and therapeutic performance. Future research is expected to focus on optimizing inhalation strategies for deep lung deposition, developing multi-targeted biomimetic carriers, advancing theranostic platforms, and employing computational tools to accelerate nanocarrier design and clinical translation. This review aims to offer critical perspectives on the development and clinical implementation of nanomedicines for LC.\u003Cbr>Keywords: lung cancer, NDDSs, organic nano-delivery systems, inorganic nano-delivery systems, inorganic-organic hybrid nanodelivery systems, targeted therapy, theranostics, clinical translation |\n| --- |\n| Introduction\u003Cbr>Lung cancer (LC), as the most prevalent malignant tumor globally, stands as the leading cause of cancer-related mortality. According to the latest estimates from the International Agency for Research on Cancer (IARC), there were nearly 2.5 million newly diagnosed LC cases in 2022, accounting for one-eighth of all global cancer cases (12.4% of total global cancers).1 Histologically, LC is primarily classified into two major subtypes: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Among these, NSCLC accounts for approximately 85% of all LC cases, while SCLC constitutes only 15%. Owing to the difficulty in early detection, high metastatic potential, and elevated recurrence risk of LC, its prognosis remains poor, with a 5-year survival rate of merely 23%. The current LC treatment paradigm is based on surgical resection, radiotherapy, and chemotherapy,2 integrated with targeted therapy and immunotherapy to form a multimodal treatment regimen. For advanced lung cancer, pharmacotherapy remains the mainstay of treatment. However, current conventional administration routes (eg, oral administration, intravenous injection) lack precision and selectivity for tumor cells, resulting in extremely low bioavailability.3 Concurrently, they induce toxic side effects on normal tissues. This scenario highlights the urgent need to develop novel drug delivery systems to address the aforementioned issues, thereby enhancing therapeutic efficacy.4\u003Cbr>Nanomedicine r","cbCaidjiu2V23KDk","https://ap.wps.com/l/cbCaidjiu2V23KDk","pdf",7949402,25,"English","# Abstract\n# Introduction\n## Lung cancer burden and current therapies\n## Role and development of nanomedicine and NDDS\n# Classification of nanocarriers","[{\"question\":\"Why are conventional lung cancer treatments limited?\",\"answer\":\"Conventional approaches like surgery, radiotherapy, and chemotherapy can suffer from poor tumor selectivity, low bioavailability, and severe systemic toxicity, which reduces treatment efficacy.\"},{\"question\":\"What makes nanocarrier-based drug delivery systems promising for lung cancer?\",\"answer\":\"Nanocarriers provide tunable size, high specific surface area, and stimuli-responsive behavior, supporting targeted delivery, controlled drug release, and theranostic capabilities.\"},{\"question\":\"How does the review categorize nanodelivery systems for lung cancer?\",\"answer\":\"The review discusses three major classes: organic, inorganic, and inorganic–organic hybrid nanodelivery systems, highlighting their distinct properties and roles in therapy.\"}]","Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer | PDF",1790149245,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fc3cfbc9159f15d0c91d428df882d55.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/beb4fdac4d8bcd0ab4d1cede44836db7.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d92db5914127efc4efd6d5baf277991.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d98dd6004d37c3c529986cd91a92acf0.webp",980,1268]